Rohit Bhasin's questions to Mirum Pharmaceuticals Inc (MIRM) leadership • Q4 2024
Question
Rohit Bhasin, on for Mike Ulz, asked about the LIVMARLI patient mix between Alagille syndrome and PFIC in Q4, its expected evolution in 2025, and the status of expanded access PFIC patients.
Answer
CEO Chris Peetz confirmed that all U.S. expanded access PFIC patients were converted to commercial product by Q3 2024. He noted that while Alagille syndrome patients are the majority, PFIC patient starts have significantly increased since Q3, becoming a substantial contributor to new patient growth.